Clinical Trial: Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07484217) titled 'Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol' on March 16.

Brief Summary: CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.

Study Start Date: Feb. 23

Study Type: INTERVENTIONAL

Condition: Major Depressive Disorder W...